Genotype-guided chemo for metastatic pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a chemo plan that includes different drugs and adjusts the irinotecan dose based on a patient’s genetic test (UGT1A1). It’s designed for people with pancreatic cancer that has spread or cannot be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 21
- You have confirmed pancreatic cancer from biopsy or surgery
- Your cancer is advanced—locally advanced or has spread—and can be measured on scans
- You’re generally able to function day-to-day (ECOG 0 to 2) and expected to live at least 12 weeks
- Your blood, liver, and kidney tests are strong enough for chemotherapy
- You can sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding Gembrax (a combination that includes gemcitabine and nab-paclitaxel) before standard FOLFIRINOX works better than FOLFIRINOX alone in people with pancreatic cancer that has already spread. It looks at whether this “step-up first” approach improves results and is still tolerable.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a precise type of radiation therapy guided by MRI for people with locally advanced pancreatic cancer. It aims to treat the tumor while protecting nearby healthy tissue, potentially improving outcomes after chemotherapy.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This trial compares two combinations of chemotherapy drugs for people with advanced pancreatic cancer whose first treatment stopped working. The study tests whether adding oxaliplatin and bevacizumab to liposomal irinotecan works better than a standard combination.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.